ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Quick Stats
Mar 27, 202650.5
AI Score
HOLD0.21
Volume Ratio
May 11, 2026
Next Earnings
15
+ve Days (30d)
13
-ve Days (30d)
IBRX Stock Summary
Last updated Mar 27, 2026
IBRX is currently trading at $6.83, positioned above its 200-day moving average of $3.75, indicating a long-term uptrend. The stock has a 52-week range of $1.83 to $12.43.
Technical Analysis: The 50-day moving average stands at $7.64, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 45.13, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.23, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates IBRX at 50.5/100 with a HOLD recommendation.
IBRX (ImmunityBio, Inc. Common Stock) Indicators
Last updated Mar 27, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 45.13 |
| CMF (20) | -0.23 |
| ROC (10) | -12.038 |
| ADX (14) | 30.417 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | 0.047 |
| AROONOSC (14) | -7.143 |
| WILLAMS %R (14) | -72.0 |
| MFI (14) | 48.761 |
IBRX Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
IBRX Price vs Max Options Open Interest
IBRX Max Change In Options Open Interest
IBRX Options - Sort by Max open Interest (near term)
30th March 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
IBRX Daily Out of Money Options - Sort by Max open Interest (near term)
30th March 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
IBRX Daily In the Money Options - Sort by Max open Interest (near term)
30th March 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
IBRX Most Active Options by Volume(near term)
30th March 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
ImmunityBio, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
IBRX Moving Averages Analysis
ImmunityBio, Inc. Common Stock has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Mar 27, 2026
IBRX (ImmunityBio, Inc. Common Stock) Simple Moving Averages
Moving Averages are last updated Mar 27, 2026
| Days | MA |
|---|---|
| 10 | 8.19 |
| 20 | 8.5 |
| 30 | 8.6 |
| 50 | 7.64 |
| 100 | 4.91 |
| 200 | 3.75 |
IBRX Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 7.6 billion |
| Earnings/Share ($) | -0.38 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -0.2533 |
| EPS Estimate Next Year ($) | -0.02 |
| WallStreet Target Price ($) | 14.8 |
| Most Recent Quarter |
Investor continues to buy dips in $IBRX, expressing frustration with algorithmic trading. Stock expected to pump to $9.80 and potentially reach $15+ in April. Positive Phase 3 trial for Vertex (VRTX) leads to market cap increase. Questions raised about famous person not receiving Anktiva/BCG for NMIBC treatment. Anktiva seen as a game-changer in cancer treatment, highlighting FDA corruption. FDA's handling of Anktiva resubmission criticized for delays in cancer treatment. $IBRX touted as a cancer cure, potentially leading to high demand and FDA embarrassment.
Updated 2026-03-09 20:00:02